Edition:
United States

Novocure Ltd (NVCR.OQ)

NVCR.OQ on NASDAQ Stock Exchange Global Select Market

29.30USD
18 May 2018
Change (% chg)

$0.90 (+3.17%)
Prev Close
$28.40
Open
$28.45
Day's High
$29.50
Day's Low
$28.45
Volume
156,078
Avg. Vol
206,420
52-wk High
$30.25
52-wk Low
$11.05

Chart for

About

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM)... (more)

Overall

Beta: --
Market Cap(Mil.): $2,567.33
Shares Outstanding(Mil.): 90.40
Dividend: --
Yield (%): --

Financials

  NVCR.OQ Industry Sector
P/E (TTM): -- 223.30 32.53
EPS (TTM): -1.11 -- --
ROI: -40.35 -8.07 12.63
ROE: -84.37 -10.87 14.50

BRIEF-Novocure Reports Qtrly Loss Per Share $0.23

* NOVOCURE REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE

Apr 26 2018

BRIEF-Novocure Says Executive Chairman William Doyle's FY 2017 Total Compensation Was $23.8 Mln

* NOVOCURE LTD SAYS EXECUTIVE CHAIRMAN WILLIAM DOYLE'S FY 2017 TOTAL COMPENSATION WAS $23.8 MILLION - SEC FILING Source : https://bit.ly/2HiWTxC Further company coverage: (Reuters.Briefs@thomsonreuters.com)

Apr 20 2018

BRIEF-Novocure Reports Positive Top-Line Results From Stellar Phase 2 Pilot Trial In Mesothelioma

* NOVOCURE REPORTS POSITIVE TOP-LINE RESULTS FROM STELLAR PHASE 2 PILOT TRIAL IN MESOTHELIOMA

Apr 17 2018

BRIEF-NCCN Guidelines Recommend Novocure's Optune In Combination With Temozolomide

* NCCN GUIDELINES RECOMMEND OPTUNE IN COMBINATION WITH TEMOZOLOMIDE AS A CATEGORY 1 TREATMENT FOR NEWLY DIAGNOSED GLIOBLASTOMA

Mar 20 2018

BRIEF-Novocure Ltd Reports Qtrly Net Loss Per Ordinary Share Of $0.12

* Q4 EARNINGS PER SHARE VIEW $-0.11, REVENUE VIEW $53.5 MILLION -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

Feb 22 2018

BRIEF-Novocure Secures New $150 Mln Non-Dilutive Term Loan Financing

* NOVOCURE SECURES NEW $150 MILLION NON-DILUTIVE TERM LOAN FINANCING

Feb 07 2018

BRIEF-Novocure Announces Q4 And FY17 Operating Statistics And Preliminary Revenue

* NOVOCURE ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 OPERATING STATISTICS AND PRELIMINARY REVENUE

Jan 09 2018

BRIEF-Novocure Receives FDA IDE Approval For Its PANOVA 3 Phase 3 Pivotal Clinical Trial In Advanced Pancreatic Cancer

* NOVOCURE RECEIVES FDA IDE APPROVAL FOR ITS PANOVA 3 PHASE 3 PIVOTAL CLINICAL TRIAL IN ADVANCED PANCREATIC CANCER

Dec 18 2017

BRIEF-Novocure Receives Reimbursement Approval For Optune In Japan For Treatment Of Glioblastoma

* NOVOCURE RECEIVES REIMBURSEMENT APPROVAL FOR OPTUNE® IN JAPAN FOR THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA

Dec 01 2017

Earnings vs. Estimates